Does BYETTA increase the risk of hypoglycemia?
In three 30-week placebo-controlled clinical trials, patients receiving BYETTA in combination with a sulfonylurea had an increased risk of hypoglycemia (14% at 5 mcg and 36% at 10 mcg vs 3% placebo). Patients receiving BYETTA in combination with metformin plus a sulfonylurea had an increased risk of hypoglycemia (19% at 5 mcg and 28% at 10 mcg vs 13% placebo). To reduce the risk of hypoglycemia, clinicians may consider reducing the sulfonylurea dose. In a 16-week study of patients receiving BYETTA with a thiazolidinedione, the incidence of mild-to-moderate hypoglycemia compared to placebo was 11% vs 7%.
